Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
25
8
2022
Statut:
ppublish
Résumé
Most gene-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are nonreplicating vectors. They deliver the gene or messenger RNA to the cell to express the spike protein but do not replicate to amplify antigen production. This study tested the utility of replication in a vaccine by comparing replication-defective adenovirus (RD-Ad) and replicating single-cycle adenovirus (SC-Ad) vaccines that express the SARS-CoV-2 spike protein. SC-Ad produced 100 times more spike protein than RD-Ad and generated significantly higher antibodies against the spike protein than RD-Ad after single immunization of Ad-permissive hamsters. SC-Ad-generated antibodies climbed over 14 weeks after single immunization and persisted for more than 10 months. When the hamsters were challenged 10.5 months after single immunization, a single intranasal or intramuscular immunization with SC-Ad-Spike reduced SARS-CoV-2 viral loads and damage in the lungs and preserved body weight better than vaccination with RD-Ad-Spike. This demonstrates the utility of harnessing replication in vaccines to amplify protection against infectious diseases.
Identifiants
pubmed: 36001674
doi: 10.1126/sciadv.abm8563
pmc: PMC9401629
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabm8563Références
Infection. 2022 Apr;50(2):531-536
pubmed: 34626338
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Am J Ther. 2021 Aug 20;28(5):e604-e606
pubmed: 34469919
N Engl J Med. 2021 May 20;384(20):1964-1965
pubmed: 33852795
Virology. 2014 Aug;462-463:158-65
pubmed: 24996029
Sci Adv. 2021 Dec 03;7(49):eabl8213
pubmed: 34851659
Am J Hematol. 2021 Aug 1;96(8):E301-E303
pubmed: 33989437
J Immunol. 2012 Feb 1;188(3):1503-13
pubmed: 22198948
Genes (Basel). 2017 Feb 18;8(2):
pubmed: 28218713
Am J Hematol. 2021 Sep 1;96(9):1180-1182
pubmed: 34057234
Ann Intern Med. 2021 Nov;174(11):1632-1633
pubmed: 34516272
PLoS One. 2021 Jun 23;16(6):e0253487
pubmed: 34161386
Vaccines (Basel). 2021 Jan 08;9(1):
pubmed: 33429880
J Virol. 2017 Apr 28;91(10):
pubmed: 28250128
Vaccines (Basel). 2020 Aug 22;8(3):
pubmed: 32842679
Cancer Immunol Immunother. 2010 Jan;59(1):161-71
pubmed: 19621224
Viruses. 2017 Jun 13;9(6):
pubmed: 28608847
J Stroke Cerebrovasc Dis. 2021 Dec;30(12):106113
pubmed: 34547677
J Virol. 2015 Jan;89(1):669-75
pubmed: 25355873
Thromb Haemost. 2022 Feb;122(2):300-303
pubmed: 34670287
J Virol. 2017 Jan 3;91(2):
pubmed: 27807231
N Engl J Med. 2021 May 20;384(20):1965-1966
pubmed: 33861522
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Front Med. 2021 Dec;15(6):938-941
pubmed: 34595694
Am J Hematol. 2021 Sep 1;96(9):E346-E349
pubmed: 34096082
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487
Cell Mol Immunol. 2021 Apr;18(4):1061-1063
pubmed: 33633321
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Virology. 2009 Nov 25;394(2):311-20
pubmed: 19765790
Ann Emerg Med. 2021 Oct;78(4):511-514
pubmed: 34226070
Methods Mol Med. 2007;130:169-83
pubmed: 17401172
J Virol. 2005 Aug;79(16):10200-9
pubmed: 16051813
J Infect Dis. 2018 Nov 5;218(12):1883-1889
pubmed: 29982595